Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Cary C who wrote (636)	2/14/1998 7:38:00 PM
From: Mark S. Schroeder	Read Replies (1) \| Respond to of 29382

Why I like it so much........the company the product the public, its finally coming together and the company does have a few surprises in store which will reflect in the stock price very very soon. Please check the past news releases and the thread PYNG here on SI. Micheal Jacobs the company President is online to answer all questions for the shareholders. PYNG Technologies Inc. Symbol: PYT (VSE) Exchange: Vancouver Stock Exchange (Senior Board) Shares Outstanding: 6.7 million Escrowed: 3.75 million Float: 2.95 million Held by insiders: 2.0 million Public Float: 0.95 million (mostly held by doctors and medical people) Website pyng.com PYNG Technologies through its wholly owned subsidiary PYNG Medical Corp. has been developing a medical device that would allow the administration of blood and drugs to patients and war victims in trauma situations. The process is called intraosseous infusion. (Intraossenous infusion is the process of delivering fluids and medication into the bone marrow of victims of shock and trauma, when vascular access is not possible). Adult intraosseous infusion in the sternal site is currently not performed as an established protocol in the medical community either in the hospital or pre-hospital enviroment. This is because there are no devices available that are simple to use, can compensate for the various thickness of adult tissue, pierce the bone marrow to the correct depth, not interfere with the performance of CPR, establish access to the vascular system and fluid flow within 90 seconds, and remain in place during movement of a victim in an emergency situation. When a victim is in a trauma state, the veins in the body colapse making it very difficult to establish an IV stream. In a car accident situation, the victim must be rushed to the hospital so that the doctor can establish an IV through cutting into the neck or other areas. The PYNG device named FAST1 for First Access for Shock and Trauma, allows the paramedic or soldier to administer the IV immediately saving the precious minutes going to the hospital. In the combat field the hospital is even farther away. Think of the savings to society in hospital costs, grief, etc. It also enables the victim to receive fluids quicker than traditional methods. The FAST1 is placed into the sternum and pumps fluid into the body through this process known as Interoius transfusion. After 5+ years of R&D, trials, modifications, adjustments, and designs, the FAST1 is complete and the World is about to find out. The original patent was developed by the University of Southern California and licensed to Pyng Medical Corp. in 1992. Pyng has since improved on these patents and received two full patents plus an additional patent pending. MARKET NEED In the United States alone, over 600,000 people die each year from cardiac arrest, that is over one person every minute. Well over half of these victims die before reaching a hospital due in part to the difficulty in administering fluids and drugs. Trauma, which claims over 200,000 lives per year, is the country's third leading cause of death and is the leading cause of death for those between the ages of 15 and 45. It is estimated that 10% of cardiac arrest deaths and 20% of trauma deaths that could be prevented if a more rapid and effective treatment were available during the first few minutes of such emergencies. PYNG Medical Corp. has developed the first adult intraosseous infusion device trademarked FAST1. Pyng's First Access for Shock and Trauma device will allow pre-hospital emergency medical EMT's to rapidly administer life saving fluids and drugs to victims of cardiac arrest and trauma when collapsed veins and rapid loss of blood prevent the establishment of conventional intravenous access. SHARE PRICE/EARNINGS Why do medical companies trade at multiples of 30 - 50 and even higher? Because in order to recover the development costs, the markup on the product is extremely high. It is lucrative once the drug or device is complete...with profit margins of 60 - 95 percent. The PYNG FAST1 sells for $70.00 U.S. and is made for just over $14.00 U.S. resulting in a profit margin of 84%. Based on a multiple of 30-50 a share price of $9.60 to $16.00 is justified for next year. Discount this to today at 50% and we are looking at a stock price of $4.80 to $8.00. It is important to remember that for the past 5 years investors have been waiting for the completed product through all its trials and redesigns. That time has come!!!